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It has been argued that clinical depression is accompanied by reductions in cortical excitability of the left prefrontal cortex (PFC). In sup-
port of this, repetitive transcranial magnetic stimulation (rTMS), which is a method of enhancing cortical excitability, has shown antidepres-
sant efficacy when applied over the left PFC, although the overall therapeutic effects remain inconclusive. The cerebral pathophysiology of
depression is, however, not limited to dysfunctions in the PFC, thus, targeting alternative brain regions with rTMS may provide new thera-
peutic windows in the treatment of depression. Evidence from electroencephalography and lesion studies suggests that not only is the left
PFC involved in depression but also the parietal cortex and cerebellum. Furthermore, rTMS over the parietal cortex and the cerebellum
has been found to improve mood and emotional functioning, at least in healthy volunteers. We have integrated these findings in an rTMS-
oriented theoretical framework for the neurobiology of low mood and depression. To establish the possible therapeutic efficacy of this
model, whereby, for example, the application of slow rTMS over the right parietal cortex and fast rTMS over the cerebellum may be benefi-
cial in different subtypes of depression, clinical rTMS studies that target the parietal cortex and cerebellum are warranted.
On a soutenu que des réductions de l’excitabilité corticale du cortex préfrontal gauche (CPF) accompagnent la dépression clinique. À
l’appui de cette affirmation, on a montré l’effet antidépresseur efficace de la magnétostimulation transcrânienne répétitive (MSTr), moyen
d’améliorer l’excitabilité corticale, appliquée au CPF gauche, même si les effets thérapeutiques globaux demeurent non concluants. La
pathophysiologie cérébrale de la dépression n’est toutefois pas limitée aux dysfonctions du CPF et c’est pourquoi l’application de la
MSTr à d’autres régions du cerveau pourrait offrir de nouveaux moyens de traiter la dépression. Les données électroencéphalo-
graphiques et tirées d’études de lésions indiquent que non seulement le CPF gauche intervient dans la dépression, mais aussi le cortex
pariétal et le cervelet. De plus, la MSTr appliquée au cortex pariétal et au cervelet améliore la thymie et l’adaptation affective, du moins
chez des volontaires en bonne santé. Nous avons intégré ces constatations dans un cadre théorique axé sur la MSTr pour la neurobiolo-
gie de l’hypothymie et de la dépression. Pour déterminer l’efficacité thérapeutique possible du modèle lorsque, par exemple, l’application
d’une MSTr lente au cortex pariétal droit et d’une MSTr rapide au cervelet peut se révéler bénéfique dans différents sous-types de dé-
pression, des études cliniques sur la MSTr appliquée au cortex pariétal et au cervelet sont justifiées.
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Introduction
Epidemiologic studies report that clinical depression has an
annual prevalence varying from 1% to 6% in community
samples worldwide.1 Estimates of the prevalence for 1999
in the general population have shown a sharp increase in
morbidity (2.1%–7.6%), making depression one of the most
common mental disorders in industrialized countries.2 Most
treatment protocols involve the administration of pharmaco-
logic agents, ranging from tricyclic antidepressants to selec-
tive serotonin reuptake inhibitors with or without psy-
chotherapeutic support. Electroconvulsive therapy (ECT), on
the other hand, is usually reserved only for those patients
whose condition is refractory to any kind of treatment.
Although its antidepressant efficacy is quite high, reaching
a remission rate of 64%–84% in patients diagnosed with
nonpsychotic depression treated with bitemporal ECT, the
application is invasive and is accompanied by transient phys-
ical and sometimes permanent cognitive side effects.
Repetitive transcranial magnetic stimulation (rTMS), a
noninvasive technique based on focal electromagnetic induc-
tion, was introduced in 1985. Hofflich et al3 were the first to
report beneficial effects for this procedure after applying
rTMS over the left prefrontal cortex (PFC) in 2 patients with
refractory depression. Currently, the most widely used rTMS
treatment protocol involves the modulation of neural ex-
citability of the left PFC. Although recent reviews4,5 indicate
that PFC rTMS does indeed possess antidepressant efficacy,
the available data and results remain heterogeneous and in-
conclusive.
There is also evidence for a role for the parietal cortex and
the cerebellum in the complex neurocircuitry underlying
emotion and mood regulation, which is dysfunctional in de-
pression.6,7 The aims of the current article are to discuss rTMS
studies that have targeted the PFC in the treatment of depres-
sion and to consider recent research in the field of affective
neuroscience investigating the antidepressant efficacy of
rTMS when applied over the right parietal cortex and the me-
dial cerebellum. Moreover, these findings are discussed
within an rTMS-oriented framework for emotional process-
ing in depression.
Transcranial magnetic stimulation
The underlying working principles of TMS are based on 2
physical laws that were originally formulated by Ampère
and by Faraday. The first law refers to the generation of a
magnetic field, using an electric current, and the second law
describes the generation of an electric current through an al-
ternating magnetic field.5 Essentially, TMS involves applying
a brief magnetic pulse or train of pulses, the latter called
repetitive TMS (rTMS), to the scalp using a coil of wire.8
When the magnetic field of the magnetic pulse alternates
rapidly enough, a secondary electric current is induced that
alters the local electric field near conductive nerve tissue.
This secondary current, however, needs to create a strong
transmembrane potential for neurons to depolarize and gen-
erate an action potential. The effects of rTMS depend on the
stimulation parameters, which include frequency and inten-
sity. By convention, slow rTMS (≤ 1 Hz) is mostly applied to
reduce neural excitability,9 whereas fast rTMS (≥ 10 Hz) is ap-
plied to enhance neural excitability.10 Speer et al11 demon-
strated these opposite effects of slow and fast rTMS over the
dorsolateral PFC by measuring decreases and increases in re-
gional cerebral blood flow, respectively. The second parame-
ter, stimulation intensity, is usually calculated as a percent-
age relative to the motor threshold (MT). By applying TMS
over the motor cortex, muscle contractions, usually of the ab-
ductor pollicus brevis (APB), can be evoked. The MT is the
lowest stimulation intensity needed to induce APB twitches
in 5 of 10 consecutive trials.12 Stimulation intensities exceed-
ing the MT are referred to as suprathreshold rTMS, whereas
the term subthreshold rTMS designates stimulation intensi-
ties below MT. The average maximum field strength of TMS
is about 1.5–2.5 T, but this strength decays exponentially with
distance. As a result, only superficial brain tissue will be af-
fected directly. It has also been argued that the effects of sub-
threshold rTMS are more local, whereas suprathreshold
rTMS results in more widespread and distant transsynaptic
effects.13 TMS is capable of modulating networks that are
functionally connected. This was demonstrated in neu-
roimaging studies by Fox et al14 and Paus et al,15 which show
distant rTMS effects in such neural networks. rTMS may be
used not only to investigate the pathophysiology underlying
mood disorders but also to “normalize” disrupted activity in
the cerebral cortex. 
Prefrontal rTMS and depression
rTMS research on depression started with the premise of a
dysfunctional PFC in this condition.16,17 Two related concepts
have been postulated concerning the relation between
prefrontal activity and depression. It is argued by most re-
searchers and clinicians that depression involves a hypoactive
left PFC, but some suggest that a right rather than left PFC
dominance in activity is the culprit. A recent meta-analysis
by Kozel and George18 tested the antidepressant efficacy of
fast rTMS over the left PFC. They reported statistically signif-
icant effect sizes, as well as measurable clinical improvement.
The antidepressant efficacy of slow rTMS over the right PFC
has also been investigated. Klein et al19 demonstrated that
slow rTMS over the right PFC was more effective than sham
stimulation, providing evidence for the idea of a distorted
homeostasis between right and left PFC activity in depres-
sion. Because rTMS was performed on patients who were re-
ceiving or starting a medication protocol, this clinical trial
was a “potentiation” study. Recently, Burt et al5 conducted a
meta-analysis for both left and right PFC rTMS across 3 cate-
gories of studies in clinically depressed patients. The cate-
gories included (1) open and noncontrolled trials, (2) con-
trolled designs and (3) comparisons with ECT. Reductions in
the Hamilton Rating Scale for Depression (HAM-D)20 were
taken to be the dependent variables of interest. Both open
and controlled trials showed an antidepressant response ini-
tially, but the overall clinical significance was small for both
left and right PFC rTMS.
Studies that compared rTMS with ECT indicated that the
duration of stimulation might be an important factor for
achieving such clinical significance. In another meta-analysis,
McNamara et al21 also reported beneficial effects of rTMS
over the PFC, but the overall clinical significance of rTMS
treatment in depression is, according to those authors, rather
unconvincing. rTMS research on depression is, however, still
in its infancy and the extremely large stimulation parameter
range is just beginning to be explored. Burt et al,5 for instance,
suggested that the extension of the rTMS treatment sessions
beyond the traditional 1–2 weeks might result in more pro-
nounced antidepressant effects. Several other reasons could
underlie the ambivalence of current findings, and it is likely
that an effective treatment protocol has not yet been devel-
oped. Parameter settings such as stimulation frequency might
also play an important role in establishing more clinically
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relevant outcomes. For instance, fast rTMS uses frequencies
between 10 and 20 Hz, whereas for slow rTMS frequencies of
around 1 Hz are used. The total amount of pulses applied is,
however, of crucial importance: upgrading stimulation fre-
quencies to 2 Hz for slow and 25 Hz for fast rTMS should not
only result in more pronounced effects but may also reduce
interindividual variability.22
Thus, intensification of stimulation parameters could be a
first step,23 but attempts to target other brain regions involved
in the pathophysiology of depression with rTMS to explore its
therapeutic efficacy might prove to be even more important.
Introducing alternative brain regions into
clinical rTMS studies
As noted here, the antidepressant efficacy of PFC rTMS is still
inconclusive, and alternative treatment tools, such as nervus
vagus stimulation (VNS) and deep brain stimulation (DBS),
are currently being explored in preclinical and clinical trials.24
However, apart from the largely unexplored parameter
range, rTMS studies have not yet investigated other brain re-
gions involved in the pathophysiology of depression. We
would like to propose alternative brain areas as targets for
rTMS treatment in depression. Recent research suggests im-
provements in mood and emotional functioning with the ap-
plication of rTMS over the medial cerebellum25 and the right
parietal cortex.26 We will discuss further the plausibility of a
neurobiological framework of low mood and depression in-
volving the cerebellum and right parietal cortex.
The parietal cortex: evidence for a left prefrontal–right
parietal depression circuit
There is evidence from lesion and neuroimaging studies for
the involvement of the parietal cortex in depression.7,27 In par-
ticular, a hypoactive right parietal cortex has been associated
with depression. However, depending on whether depres-
sion is comorbid with anxiety, right parietal hyperactivity
has also been observed.28 This can be explained by the fact
that the right parietal cortex is involved in arousal:6 hy-
poarousal is linked to depression, whereas hyperarousal is
associated with anxiety. Problematically, a highly complex
picture emerges when depression is comorbid with anxiety,
which is often the case.29
A well-known biochemical marker for depression is cor-
tisol. Presumably because of a hyperactive hypothalamic–
pituitary–adrenal (HPA) axis, depressive as well anxious
subjects often demonstrate basal levels of this stress-related
hormone that are higher than normal.30 Moreover, Belanoff
et al31 recently demonstrated that the cortisol-receptor antago-
nist mifepristone was effective in the treatment of psychotic
depression.
Furthermore, Schutter et al32 found that higher basal levels
of cortisol are associated with reductions in functional connec-
tivity between the left prefrontal and the right parietal cortex.
This functional connectivity between different cortical brain
regions can be measured using electroencephalography.
Electroencephalographic coherence analysis33 may provide
valuable insights into the neurobiological mechanisms of de-
pression. Cerebral atrophy, for instance, which has been re-
ported in depression,34 is accompanied by a breakdown in
functional corticocortical connectivity.35
Recently, an rTMS experiment was conducted to investi-
gate the involvement of the right parietal cortex in depres-
sion. In healthy human subjects, the application of 2-Hz
rTMS over the right parietal cortex for 20 minutes contin-
uously resulted in statistically significant decreases in self-
reported, attentional and psychophysiologic indices of de-
pressive mood compared with placebo.26
The fact that reductions in several indices of depressive
mood have been found in healthy control subjects after a sin-
gle session of rTMS suggests a possible antidepressant effi-
cacy, although it must be noted that rTMS-induced effects on
mood might differ between healthy controls and clinically
depressed subjects. These findings, however, are consistent
with those of a study by Schutter et al32 that showed that high
levels of cortisol are related to reductions in functional con-
nectivity between the left prefrontal and the right parietal
cortex. Moreover, there are indications that the antidepres-
sant properties of the steroid hormone testosterone36 are asso-
ciated with increases in functional connectivity in this left
prefrontal–right parietal circuit.37 We think that these data,
when taken together with the observation made by Jing and
Takigawa38 that functional connectivity between the left pre-
frontal and right parietal brain regions is enhanced by left
PFC rTMS, support the need for clinical rTMS trials in de-
pression targeting the right parietal cortex.
In summary, recent research from multiple disciplines sug-
gests that the functional connectivity between the left pre-
frontal and right parietal cortex plays a role in depressive
mood. Moreover, the antidepressant effects of rTMS studies
over the left PFC and recently observed improvements in
mood and emotional functioning after rTMS over the right
parietal cortex might both involve increased functional con-
nectivity between these cortical brain areas.39,40
The cerebellum
For decades, the cerebellum has been thought to be predomi-
nantly involved in motor performance and cognitive opera-
tions. Recently, however, a growing body of evidence indi-
cates that the cerebellum is also involved in emotion. The
first evidence for cerebellar involvement in emotion came
from the work of Robert G. Heath during the early fifties. Al-
though his initial work predominantly involved the electrical
stimulation of the septum, he then began research on stimu-
lation of the cerebellum, thinking that it might provide a bet-
ter entry to the emotional circuitry of the brain. Several cere-
bellar pacemaker studies by Heath41 and by Heath et al42 did
indeed demonstrate positive effects on mood and personality
in patients with psychiatric illness after electrical stimulation
of the cerebellum. Moreover, Schmahmann and Sherman43
provided clinical support for the role of the cerebellum and
particularly the vermis in the regulation of emotion and
mood. Given its modulatory role on emotion, the midline
cerebellar vermis together with the fastigial nucleus and the
flocculonodular lobe have been designated the limbic cere-
bellum.44 Furthermore, additional evidence for the involve-
ment of the cerebellum in mood disorders, such as de-
pression, was provided by structural magnetic resonance
imaging studies. Unipolar depression is not only associated
with volumetric reductions of the frontal lobes but also of the
cerebellum.45 Leroi et al46 recently found further evidence for
this cerebellum–depression relation. In a study of patients
with degenerative cerebellar diseases, comprehensive psychi-
atric evaluations revealed that depressive disorders were as-
sociated with cerebellar degeneration. Starkstein et al47 found
evidence for a relation between cerebrovascular lesions in the
posterior brain structures, including the cerebellum, and de-
pression. Beyer and Krishnan48 recently concluded after re-
viewing the literature that depression is associated with ab-
normalities in the frontal lobes, the basal ganglia and the
cerebellum. Given the structural deviations of the cerebel-
lum, functional abnormalities are likely to be present also.
However, reports of functional cerebellar deviances are lack-
ing, most probably because of the practice of using the cere-
bellum as a reference for cerebral perfusion and activation
patterns.44 Interestingly, however, studies by Schmahmann
and Pandya49 and by Middleton and Strick50 demonstrated
that the cerebellum and the PFC are anatomically linked in a
bidirectional fashion. The first loop consists of the thalamus,
which receives efferent input from the cerebellum and pro-
jects to the PFC. The circuit is closed via prefrontal projec-
tions back to the cerebellum via the pontine nucleus of the
brain stem.49,50 Recently, Schutter et al25 investigated the exis-
tence of the assumed projection from the medial cerebellum
to the PFC in healthy human subjects using fast rTMS and
electroencephalography. rTMS targeting the medial part of
the cerebellum indeed modulated ongoing electrical activity
in the PFC. Interestingly, in the latter study, elevations in
mood and alertness were reported spontaneously after me-
dial cerebellar stimulation exclusively. Animal studies have
provided support for cerebellar modulation via the mesen-
cephalic reticular formation of EEG patterns and levels of
alertness.51 The findings of Schutter et al25 not only provide
the first evidence for a cerebelloprefrontal link in humans,
but the observed increases in mood are also a further indica-
tion for a role of the cerebellum in regulation of affect.
Because the cerebellum has efferent pathways to the substan-
tia nigra, and depression has been linked to deficiencies in
the biogenic monoamines, cerebellar rTMS in the study by
Schutter et al25 might have stimulated dopamine release, re-
sulting in the observed changes in PFC activity and the eleva-
tions in alertness and mood. In support of this, Keck et al52
applied 20-Hz rTMS in rats over the left frontal cortex and
observed increases in the release of dopamine in both the
mesolimbic and the mesostriatal system. Because there is evi-
dence for dopaminergic effects of cerebellar stimulation,53 it is
likely that the elevations in alertness and mood after cerebel-
lar rTMS in the study by Schutter et al25 may be explained
in terms of dopaminergic stimulation. In sum, the evidence
suggests a role for the cerebellum in clinical depression, and
mood improvements after fast cerebellar rTMS have recently
been shown in healthy volunteers. Therefore, fast cerebellar
rTMS might be explored as method for the treatment of clini-
cal depression.
An rTMS-oriented theoretical framework for
the treatment of depression
Until now, the PFC has been the main target in the investiga-
tion of the therapeutic application of rTMS in depression. It
has been argued that enhanced turnover of dopamine in par-
ticular in the subcortical structures may contribute largely to
the beneficial effects of rTMS. Although PFC rTMS has
demonstrated antidepressant properties, its overall clinical
efficacy is not yet clear. This might be the result of the lack of
insight regarding the precise physiologic mechanisms by
which rTMS establishes its effects, as well as the difficult type
of patient population that receives stimulation, because these
subjects normally have failed to benefit from all conventional
treatment. Furthermore, stimulation parameters could also
play an important role in the inconsistencies found and the
lack of therapeutic efficacy.54 Given the high interindividual
variability in both functional as well as structural anatomy,
the use of higher frequency rates and longer stimulation
times should induce more stable and stronger effects.22 The
problematic issue of safety, however, puts a constraint on the
stimulation parameter settings that can be used in humans.4
However, triggering seizures or inducing kindling through
magnetic stimulation is not very easy to accomplish, at least
in healthy subjects.55 Further exploring the possibilities of the
safe use of rTMS at more intense stimulation parameters,
such as higher frequency rates and longer duration, might be
worthwhile.56
As noted, alterations in dopamine levels seem to be in-
volved in the pathogenesis of depression;57 there is, in particu-
lar, a growing body of evidence for the association between
depression and lowered dopaminergic activity.58 Thus, it is of
interest that animal research indicates that the antidepressant
effects of left PFC rTMS are probably caused by enhanced
dopaminergic activity.52 Further evidence for enhanced
dopaminergic activity after rTMS was recently provided by
Zangen and Hyodo.59 Interestingly, however, these authors
showed that stimulation over the caudal cortex caused a
greater increase in dopamine levels than stimulation over the
frontal cortex, which led them to suggest that the caudal parts
of the cortex could have a greater potential for establishing an-
tidepressant efficacy. This evidence from animal research sug-
gests that the PFC might not be the ideal target location for
rTMS in depression. There is evidence for the involvement of
interconnected structures in depression, including the parietal
cortex,30,31 the cerebellum and various subcortical nuclei.42 Un-
fortunately, direct subcortical stimulation is not yet an issue for
rTMS research, because of the fast decay of the magnetic field
with distance. On the basis of findings from direct stimulation
studies carried out in human healthy volunteers,25,26 patients42
and animals,52 it is, however, reasonable to assume that the
clinical application of rTMS over the parietal cortex and cere-
bellum might be a worthwhile venture. Currently, clinical
slow and fast rTMS treatment studies in depressed patients
targeting the right parietal cortex and cerebellum are being
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prepared in our laboratory to further investigate the therapeu-
tic efficacy of rTMS and the neural mechanisms underlying the
pathophysiology of depression.
In the final section of this paper, we would like to postulate
a hypothetical model for rTMS research in the domain of de-
pression that builds on the specific involvement of the PFC,
right parietal cortex and cerebellum. The findings presented
here suggest that these structures and their reciprocal con-
nectivity are part of a neurocircuitry that is dysfunctional in
depression. Figure 1 depicts this heuristic working frame-
work for rTMS applications in the treatment of depression,
which includes, besides the PFC, the right parietal cortex and
the cerebellum. It should be noted that the framework is lim-
ited, because it focuses primarily on regions directly reach-
able by rTMS and on the involvement of the neurotransmit-
ter dopamine. The connections outlined in Figure 1 are based
on neuroimaging and rTMS electrophysiologic studies.
This rTMS-oriented theoretical framework enables us to
distill several hypotheses regarding potential efficient antide-
pressant stimulation parameters. Moreover, the model might
actually predict antidepressant efficacy for different subtypes
of depression when applying rTMS with specific stimulation
parameters over selected brain regions. A hyperactive right
parietal cortex has, for instance, been implicated in comorbid
depression and anxiety.28 On the basis of the premise that 2-
Hz rTMS over the right parietal cortex is capable of dampen-
ing cortical arousal and enhancing functional corticocortical
connectivity with the left PFC, slow rTMS might be especially
effective in the treatment of this subtype of depression. Fur-
thermore, elevations in mood and alertness after fast cerebel-
lar rTMS25 are arguably the result of increased dopaminergic
activity, hence, apathetically depressed patients may benefit
from this kind of high-frequency stimulation. On the other
hand, bipolar disorder could be treated by both slow and fast
rTMS depending on the state of illness. Using carefully se-
lected stimulation parameter settings, dopamine could be
partly enhanced or blocked, in bipolar disorder, in an at-
tempt to set the brain properly and thus achieve euthymic
stabilization. Although these hypotheses are speculative and
need further verification, our aim was to develop a progres-
sive theoretical approach for clinical rTMS research that is ca-
pable of linking subtypes of depression to different rTMS
treatment protocols.
After a decade of research, rTMS over the PFC has proven
to be superior to sham stimulation in reducing depressive
psychopathology, but the clinical efficacy remains inconclu-
sive as of yet.60 In the present overview, a framework is pos-
tulated for investigating alternative brain regions by rTMS in
clinical depression. A possible antidepressant efficacy is hy-
pothesized for both slow rTMS over the right parietal cortex
and fast rTMS over the cerebellum.
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